Promimic and Danco signed a license agreement whereby Danco will invest in a production line for the HAnano Surface process developed by Promimic. Danco will be the preferred process partner for Promimic for the U.S. and China medical implant markets.
The HAnano Surface is 20 nanometers thin and has demonstrated the ability to improve and accelerate osseointegration in >20 pre-clinical studies. Through its wet chemical process, it can be applied to almost any implant material and shape to support integration with bone.
“We’re excited to partner with Danco and I’m convinced that this will create a faster spread for our technology to implant companies both in USA and in China,” said Ulf Brogren, Promimic’s CEO.
The nanotechnology industry is growing at a rapid pace, with reports claiming varying revenues between $300 billion to $3 trillion. The projected evolution of nanotechnology in orthopaedics includes surface treatments, biologics, antimicrobial components and sensors. The main goals are to develop an implant that the body responds to faster and to develop an implant that decreases the chance for infection. While most companies are focused on its use in spine, an advantage of nanotechnology is that it can be widely used throughout the body.
To learn more about nanotechnology and its developing role in orthopaedics, read, “The Future of Nanotechnology in Orthopaedics.”